XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
R
R

Roche

市场新闻

Reuters - 2天前

Financial Times - Oct 1

PRESS DIGEST- Financial Times - Oct 1 Oct 1 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Simon Case steps down as UK cabinet secretary - EY picks Anna Anthony as UK boss after three-way race - Roche plans to launch drugs and slash development costs - LVMH sells Off-White streetwear brand founded by Virgil Abloh - Qatar Airways agrees to buy 25% stake in Virgin Australia Overview Sim
L
R
Reuters - 3天前

Roche targets more than $3 billion in annual obesity sales

UPDATE 1-Roche targets more than $3 billion in annual obesity sales Releads By Ludwig Burger FRANKFURT, Sept 30 (Reuters) - Roche ROG.S said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billion) in annual sales . In a presentation to investors, the Swiss drugmaker said the revenue projection applies on aggregate to weekly injection CT-388 - which is similar t
R
Reuters - 3天前

Roche aims to slash drug development time and costs by 2030

Roche aims to slash drug development time and costs by 2030 FRANKFURT, Sept 30 (Reuters) - Swiss drugmaker Roche ROG.S said on Monday it aims to slash the development costs of drugs it brings to market and speed up their development time by 2030. Average development costs of a drug that is launched should decline by 20% and the time from early drug discovery to the end of Phase 3 testing on humans would be cut by 40%, according to presentation slides posted on the company's website.
R
Reuters - 1周前

Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis

BRIEF-Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis Sept 26 (Reuters) - Roche Holding AG ROG.S : POSITIVE PHASE III RESULTS FOR GENENTECH’S GAZYVA SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS Source text for Eikon: ID:nBw2HSqmRa Further co
R
Reuters - 1周前

Vontobel raises Roche to 'buy' ahead of expected strategy update

BUZZ-Vontobel raises Roche to 'buy' ahead of expected strategy update ** Vontobel raises Roche ROG.S to "buy" from "hold" based on the Swiss drugmaker's planned R&D cost controls and ahead of its expected strategy update at the end of the month ** The company's Pharma Day on Sept. 30 is the key event to understanding how the new leadership will run
R
Reuters - 1周前

Roche Says Positive Phase III Results For Gazyva/Gazyvaro Show Superiority To Standard Therapy Alone In People With Lupus Nephritis

BRIEF-Roche Says Positive Phase III Results For Gazyva/Gazyvaro Show Superiority To Standard Therapy Alone In People With Lupus Nephritis Sept 26 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE PHASE III RESULTS FOR ROCHE’S GAZYVA/GAZYVARO SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS REGENCY STUDY MET ITS PRIMARY ENDPOI
R
Reuters - 1周前

ROche: WHO Endorses Dual-Stain Cytology Testing In Its Cervical Cancer Prevention Guidelines

BRIEF-ROche: WHO Endorses Dual-Stain Cytology Testing In Its Cervical Cancer Prevention Guidelines Sept 23 (Reuters) - ROCHE HOLDING AG ROG.S : WHO ENDORSES DUAL-STAIN CYTOLOGY (CINTEC PLUS) TESTING IN ITS CERVICAL CANCER PREVENTION GUIDELINES, ADVANCING PATIENT CARE AND UNDERLINING ROCHE’S ROLE IN PIONEERING CERVICAL CANCER SOLUTIONS Source text
R
Reuters - 2周前

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

UPDATE 1-Sanofi's tolebrutinib drug delays progressive MS by 31% in trial Adds details and background throughout By Ludwig Burger FRANKFURT, Sept 20 (Reuters) - Sanofi SASY.PA said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
N
R
S
Reuters - 2周前

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S
Reuters - 2周前

Swiss stocks - Factors to watch on September 19

Swiss stocks - Factors to watch on September 19 ZURICH/GDANSK, September 19 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ROCHE HOLDING AG ROG.S Roche says phase III results show Xofluza significantly reduces the transmission of influenza viruses. RICHEMONT CFR.S - 2.75 CHF/shr dividend ECONOMY Swiss August trade balance due at 0600 GMT.
A
R
R
S
Reuters - 2周前

Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses

BRIEF-Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses Sept 19 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE PHASE III RESULTS SHOW XOFLUZA SIGNIFICANTLY REDUCES THE TRANSMISSION OF INFLUENZA VIRUSES DATA FROM CENTERSTONE STUDY SHOWS SINGLE-DOSE XOFLUZA REDUCES TRANSMISSION OF INFLUENZA FROM AN I
R
Reuters - 2周前

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit
B
H
N
R
S
S
Z
Reuters - 2周前

Roche Says FDA Approves Ocrevus Zunovo™

BRIEF-Roche Says FDA Approves Ocrevus Zunovo™ Sept 16 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES OCREVUS ZUNOVO™ AS THE FIRST AND ONLY TWICE-A-YEAR 10-MINUTE SUBCUTANEOUS INJECTION FOR PEOPLE WITH RELAPSING AND PROGRESSIVE MULTIPLE SCLEROSIS THIS APPROVAL IS BACKED BY A DECADE OF PROVEN SAFETY AND EFFICACY DATA OF OCREVUS® IV, WITH OVER
R
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 3周前

FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis

BRIEF-FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis Sept 13 (Reuters) - Genentech: FDA APPROVES OCREVUS ZUNOVO™ AS THE FIRST AND ONLY TWICE-A-YEAR 10-MINUTE SUBCUTANEOUS INJECTION FOR PEOPLE WITH RELAPSING AND PROGRESSIVE MULTIPLE SCLEROSIS Source text for Eikon: ID:nBw29jVlta
R
Reuters - 3周前

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F
Reuters - 3周前

FDA Approves Roche’s Tecentriq Hybreza

BRIEF-FDA Approves Roche’s Tecentriq Hybreza Sept 13 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES ROCHE’S TECENTRIQ HYBREZA, THE FIRST AND ONLY SUBCUTANEOUS ANTI-PD-(L)1 CANCER IMMUNOTHERAPY TECENTRIQ HYBREZA PROVIDES PATIENTS AND PHYSICIANS WITH GREATER FLEXIBILITY OF TREATMENT OPTIONS WHILE SHOWING SAFETY AND EFFICACY CONSISTENT WITH INT
R
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。